Misleading offers
An offer needs more than reassuring words.
Take the offer apart into the assessment, the medicine, the pharmacy, and the payment. Ask for a clear answer about each.
Check the claims before choosing care
Question claims that blur the medicine
The claim to question is that a compounded drug and an approved drug are the same. The Food and Drug Administration (FDA) called that false or misleading, as checked September 26, 2026.
- A claim that a compounded preparation is FDA-approved is false.
- Products offered for treatment under a “research use only” label have unknown quality; the FDA warns people against obtaining them.
- No U.S. generic tirzepatide had approval on September 26, 2026.
Find out who supplies the medicine
Semaglutide is another medicine; Ozempic and Wegovy are among its brand names. The FDA has found made-up pharmacy details on compounded tirzepatide and semaglutide labels. Some labels name a pharmacy that does not even exist.
- Before payment, request the full name of the dispensing pharmacy.
- Use the state pharmacy board record to check it.
- Finding a pharmacy’s licence does not prove it supplies medicines properly.
Check how questions and payments work
FDA warning signs include no required prescription, no clinician available for later questions, and damaged medicine packaging.
- Even a convincing health-site seal or logo can be forged, according to the Federal Trade Commission.
- Ask for the full charge, the cancellation terms, and a way to get answers to questions.
- Pause the comparison while important answers are missing.